<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465944</url>
  </required_header>
  <id_info>
    <org_study_id>FFP104-002</org_study_id>
    <secondary_id>2015-001678-17</secondary_id>
    <nct_id>NCT02465944</nct_id>
  </id_info>
  <brief_title>A Pilot Study of FFP104 in Subjects With Crohn's Disease</brief_title>
  <official_title>A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fast Forward Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fast Forward Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability and efficacy of&#xD;
      intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with&#xD;
      moderate to severely active Crohn's Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed through clinical laboratory tests, vital signs, physical exams, and adverse event assessments</measure>
    <time_frame>Up to 84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical response (decrease of Crohn's Disease Activity Index (CDAI) score by ≥100 points from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical remission (attainment of absolute CDAI score of 150 points or less from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving partial response (decrease of CDAI score by &gt;70 points from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CDAI score between FFP104 treated subjects and placebo subjects in each arm of the study</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (decrease in CDAI score by &gt;100 points)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to partial response (decrease of CDAI score by &gt;70 points)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gut tissue organisation (histology)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in faecal calprotectin level</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in C-Reactive Protein (CRP) levels</measure>
    <time_frame>Day 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health outcome measures</measure>
    <time_frame>Day 42</time_frame>
    <description>Health outcome measures that will be used are Short Form 36 (SF36), the EuroQol EQ-5D-5L and the Work Productivity and Activity Impairment Questionnaire Crohn's Disease (WPAI-CD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes from baseline in serum FFP104 levels</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes in lymphocyte sub-populations in peripheral blood</measure>
    <time_frame>Day 0, 14 and 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>FFP104 - 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FFP104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFP104 - 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FFP104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFP104</intervention_name>
    <description>Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)</description>
    <arm_group_label>FFP104 - 2.5 mg/kg</arm_group_label>
    <arm_group_label>FFP104 - 5.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Subjects will be entered into this study only if they meet all of the following criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Willing and able to comply with all study procedures and visits.&#xD;
&#xD;
          -  Male or female aged between 18 and 75 years, inclusive.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18-35 kg/m2.&#xD;
&#xD;
          -  Clinical diagnosis of Crohn's disease involving the colon and/or ileum for at least 3&#xD;
             months from Screening confirmed by radiological, endoscopic or histological evidence.&#xD;
&#xD;
          -  Active Crohn's disease defined as a Crohn's Disease Activity Index (CDAI) score from&#xD;
             220 and 450, inclusive, at Screening.&#xD;
&#xD;
          -  Active inflammatory disease as defined by Crohn's Disease Endoscopic Index of Severity&#xD;
             (CDEIS) ≥ 8 (as determined by a Central Blinded Reader) at Screening.&#xD;
&#xD;
          -  Tumor Necrosis Factor (TNF)-naïve or previously exposed to a single anti-TNF agent&#xD;
             (such as infliximab, adalimumab or certolizumab pegol) with treatment discontinued at&#xD;
             least 8 weeks prior to Screening due to inadequate response, loss of response or&#xD;
             intolerance as judged by the Investigator.&#xD;
&#xD;
          -  Must have adequate renal and hepatic function as adjudged by the Investigator.&#xD;
&#xD;
          -  In good health (other than Crohn's disease) as evidenced by medical history and&#xD;
             physical examination.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Subjects will be entered into this study only if they meet none of the following criteria:&#xD;
&#xD;
          -  Subjects who are pregnant, breastfeeding, or of child-bearing potential and not using&#xD;
             a medically accepted form of contraception.&#xD;
&#xD;
          -  Presence of fistulas, ileostomies, colostomies or rectal pouches or history of&#xD;
             proctocolectomy or total colectomy. Subject has an ostomy or ileoanal pouch (subjects&#xD;
             with a previous ileorectal anastomosis are not excluded).&#xD;
&#xD;
          -  Subject has short bowel syndrome as determined by the Investigator.&#xD;
&#xD;
          -  History of evidence of colonic mucosal dysplasia.&#xD;
&#xD;
          -  Subject currently has a significant mechanical obstruction (stenosis).&#xD;
&#xD;
          -  Subject has a current diagnosis of ulcerative or indeterminate colitis.&#xD;
&#xD;
          -  Immunization with a live vaccine within 4 weeks of Screening, with the exception of&#xD;
             influenza vaccine and no planned immunizations within the period of the study.&#xD;
&#xD;
          -  Active or latent tuberculosis (TB) or tuberculosis infection; TB assessment and&#xD;
             prophylaxis will be performed as per local biologicals regulations and guidelines.&#xD;
&#xD;
          -  Subjects with a history of or ongoing chronic or recurrent infectious disease within&#xD;
             the 12 months prior to Screening.&#xD;
&#xD;
          -  Positive stool culture for Clostridium within the last 6 months prior to Screening.&#xD;
&#xD;
          -  Use of prohibited medications/procedures, including;&#xD;
&#xD;
               -  Concomitant corticosteroids doses exceeding 20 mg/day of prednisone (equivalent)&#xD;
&#xD;
               -  Concomitant use of budesonide&#xD;
&#xD;
               -  Concomitant use of anti-TNF therapy&#xD;
&#xD;
               -  Subjects who received previous treatment with more than one anti-TNF agent&#xD;
&#xD;
               -  Concomitant use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil&#xD;
&#xD;
               -  Prior or concomitant use of anti-α4 integrin or other non-TNF blocking biological&#xD;
&#xD;
               -  Use of tube or enteral feeding, elemental diet, or parenteral alimentation&#xD;
                  started within 2 weeks prior to Screening&#xD;
&#xD;
               -  Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening&#xD;
&#xD;
          -  Use of any prescription medications/products (with the exception of prescription&#xD;
             medications for contraception and/or medications deemed acceptable by the Investigator&#xD;
             and Sponsor).&#xD;
&#xD;
          -  Use of any over the counter (OTC), non-prescription preparations (including vitamins,&#xD;
             minerals, phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to&#xD;
             the Check-in visit (Day 0), unless deemed acceptable by the Investigator and Sponsor.&#xD;
&#xD;
          -  Current or recent history (within 6 months of screening) of drug or substance abuse,&#xD;
             including alcohol ≥ 14 units per week or who have a significant history of alcoholism&#xD;
             or drug/chemical abuse within 6 months prior to the Screening visit (one unit of&#xD;
             alcohol equals 0.5 pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1&#xD;
             shot [25 mL] of spirits).&#xD;
&#xD;
          -  Subjects with known clinically significant cardiac disease (e.g., myocardial&#xD;
             infarction or stroke within 6 months prior to Screening, unstable angina,&#xD;
             claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG)&#xD;
             abnormality at Screening.&#xD;
&#xD;
          -  A history of significant neurologic, hepatic, renal, endocrine, cardiovascular,&#xD;
             gastrointestinal, pulmonary or metabolic disease within 30 days of the Screening&#xD;
             visit, as judged by the Investigator.&#xD;
&#xD;
          -  Have a family history (more than one first degree relative) of multiple thrombotic&#xD;
             events or a personal history of any venous or arterial thrombotic event including deep&#xD;
             vein thrombosis, stroke, myocardial infarction, pulmonary embolus, and peripheral&#xD;
             arterial thromboembolic events.&#xD;
&#xD;
          -  Subject has had a positive hepatitis panel (including hepatitis B surface antigen&#xD;
             [HBsAg], hepatitis B core antibody, and hepatitis C virus antibody [anti-HCV]) or a&#xD;
             positive HIV antibody screen at time of Screening.&#xD;
&#xD;
          -  Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of&#xD;
             liver disease including non-alcoholic steatohepatitis (NASH) or abnormal hepatic&#xD;
             markers (AST, ALT, ALP, or total bilirubin &gt; 1.5 x upper limit of normal) at the time&#xD;
             of the Screening visit.&#xD;
&#xD;
          -  Abnormal renal function (BUN or creatinine &gt;1.25 x upper limit of normal) at the time&#xD;
             of the Screening visit.&#xD;
&#xD;
          -  White Blood Cells &lt;4 x 103/mm3; platelets &lt;150 x 103/mm, hemoglobin &lt; 6.2 mmol/L at&#xD;
             the time of the Screening visit.&#xD;
&#xD;
          -  Subjects with evidence of other serious, significant, acute or chronic medical or&#xD;
             psychiatric illness that, in the judgment of the Investigator, could compromise&#xD;
             subject safety, limit the subject's ability to complete the study, and/or compromise&#xD;
             the objectives of the study.&#xD;
&#xD;
          -  History of malignancy, with the exception of resected basal cell carcinoma, squamous&#xD;
             cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.&#xD;
&#xD;
          -  Active acute infection requiring systemic treatment for more than 2 weeks.&#xD;
&#xD;
          -  Planned surgery during the study period or have undergone major surgery within the 3&#xD;
             months prior to the Screening visit.&#xD;
&#xD;
          -  Subjects who have received any investigational drug within 60 days or use of other&#xD;
             experimental anti-CD therapies within the last 30 days prior to Screening visit.&#xD;
&#xD;
          -  Known sensitivity to any component of the study drug or previous sensitivity reaction&#xD;
             or other clinically significant reaction to intravenous medications or biologic&#xD;
             therapy.&#xD;
&#xD;
          -  Subjects who have previously received FFP104 or have been previously enrolled in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gert van Assche, Prof. Dr.</last_name>
      <phone>+32 16 34 42 25</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneke van der Woude, Prof. Dr.</last_name>
      <phone>+31 107040126</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

